Third Rock Ventures III, L.P. 4
4 · Nurix Therapeutics, Inc. · Filed Jul 29, 2020
Insider Transaction Report
Form 4
Third Rock Ventures III, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-07-28+875,000→ 875,000 total - Conversion
Common Stock
2020-07-28+39,216→ 5,422,549 total - Conversion
Series B Preferred Stock
2020-07-28−4,508,333→ 0 total→ Common Stock (4,508,333 underlying) - Conversion
Common Stock
2020-07-28+4,508,333→ 5,383,333 total - Conversion
Series A-2 Preferred Stock
2020-07-28−875,000→ 0 total→ Common Stock (875,000 underlying) - Conversion
Series D Preferred Stock
2020-07-28−39,216→ 0 total→ Common Stock (39,216 underlying)
Footnotes (2)
- [F1]The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]The shares are directly held by Third Rock Ventures III, L.P. ("TRV III"). The general partner of TRV III is Third Rock Ventures GP III, L.P. ("TRV GP III"). The general partner of TRV GP III is TRV GP III, LLC ("TRV GP III LLC"). The individual managers of TRV GP III LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP III, TRV GP III LLC, Levin, Starr and Tepper disclaims beneficial ownership of these shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.